JGGCDN

French energy giant TotalEnergies says it will no longer aim to reach net zero emission targets by 2050 bloomberg.com/news/articles/…

Conservatives put pressure on Carney to clarify his position on forced labour in China theglobeandmail.com/politics/artic…

Glow Lifetech $GLOW.C cleaned up its capital structure: 41M+ warrants reduced in Q1 2026 5M options (Expired unexercised) 10.9M warrants exercised 89% by insiders & long term holders Cuts dilution 16.6% over the trailing twelve months. “This significant reduction in our warrant and option overhang marks an important milestone for Glow… we are well-positioned to advance into our next phase of growth.” - CEO Rob Carducci glowlifetech.com/news/glow-life…

$NPTH.V — NeuPath Health Inc. | FY & Q4 2025 Results One of Canada's largest chronic pain & sports medicine clinic networks — 28 consecutive quarters of positive Adjusted EBITDA. 📊 FY 2025 Highlights: • Revenue: $87.2M (+20% YoY) — record year • Gross margin: 19.0% (flat YoY) • Adjusted EBITDA: $6.0M (+56% YoY) • Operating cash flow: $4.0M (vs. $2.6M in 2024) • Net loss (shareholders): -$0.7M (improved from -$0.7M in 2024) • Capacity utilization: 82% (vs. 75% in 2024) ⚡ Q4 2025 Highlights: • Revenue: $22.1M (+17% YoY) — 28th consecutive quarter of positive Adj. EBITDA • Gross margin: 18.3% (vs. 19.2% Q4 2024) • Adjusted EBITDA: $1.0M (+9% YoY) • Cash: $4.5M | Net debt: $1.7M (down from $3.0M a year ago) 🏥 Operational: • Physical capacity utilization: 52% in Q4 (vs. 47% in Q4 2024) — new reporting metric introduced • Arthrosamid injectable joint treatment now live and contributing to clinic revenue growth • AI medical scribes deployed to improve physician utilization 🔮 Outlook: • New CEO Stephen Lemieux stepping in from President role • Expects continued revenue growth and margin improvement in 2026 • Focus on new clinic locations and expanding Arthrosamid availability neupath's revenue is compounding fast — 20% growth on top of a larger base, and OCF more than doubled year over year. The balance sheet is light ($1.7M net debt) and the business generates real cash. With physical capacity still at only ~52%, there's meaningful room to grow without major capital outlays. Margin flatness in Q4 bears watching, but the trajectory is clear. Full analysis: investorlens.io/stocks/NPTH.V #TSXV #CanadianStocks #Healthcare #SmallCap #ChronicPain

Last Monday I shared a custom P123 Skill for Claude. 25,000+ views. 260+ likes. Hundreds of DMs. The #1 question I got: "How did you build this?" Here's the truth: it's simpler than you think. A Skill is just a folder with a SKILL.md file. You write instructions in Markdown, add reference docs if needed, ZIP it, and upload it in Claude.ai under Customize > Skills. That's it. Claude reads your instructions and becomes a specialist in whatever domain you taught it. For my @P123Finance Skill, I packed in: → The full formula language (445+ functions) → The complete API documentation → Ranking system logic, universe definitions, screen rules → Python code patterns for the API Now Claude can write, debug, and optimize P123 formulas like someone who's been using the platform for years. You can do this for ANY domain. Your company's internal tools, your investment process, your research workflow. Anything you explain well, Claude can learn. Here's a step-by-step visual showing exactly how it works 👇 @AnthropicAI @claudeai